Data

Treatment of clozapine associated obesity and diabetes with exenatide in people with schizophrenia

Health Data Australia Contributor Records
Siskind, Dan ; Mental Health Node
Viewed: [[ro.stat.viewed]] Cited: [[ro.stat.cited]] Accessed: [[ro.stat.accessed]]
ctx_ver=Z39.88-2004&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Adc&rfr_id=info%3Asid%2FANDS&rft_id=info:doi10.26187/9JYE-P948&rft.title=Treatment of clozapine associated obesity and diabetes with exenatide in people with schizophrenia&rft.identifier=http://doi.org/10.26187/9JYE-P948&rft.publisher=University of Queensland&rft.description=Twenty-eight outpatients with schizophrenia (aged 18-64 years) were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks. The primary outcome was proportion of participants with >5% weight loss. All 28 participants completed the study; 3/14 in the exenatide group and 2/14 in the usual care group had type 2 diabetes.&rft.creator=Siskind, Dan &rft.creator=Mental Health Node &rft.date=2019&rft.relation=https://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?ACTRN=ACTRN12615000524594&rft.type=dataset&rft.language=English Access the data
Cite Saved to MyRDA Save to MyRDA

Full description

Twenty-eight outpatients with schizophrenia (aged 18-64 years) were randomized to once-weekly extended-release subcutaneous exenatide or usual care for 24 weeks. The primary outcome was proportion of participants with >5% weight loss. All 28 participants completed the study; 3/14 in the exenatide group and 2/14 in the usual care group had type 2 diabetes.

Notes

HeSANDA 1.0.0

This dataset is part of a larger collection

Click to explore relationships graph
Help

Related Publications

Related People

User Contributed Tags    

Login to tag this record with meaningful keywords to make it easier to discover

Identifiers
Similar data you may be interested in: